Dale N. Gerding, MD

Closing out their discussion on recurrent clostridium difficile infection management, experts share closing thoughts and hopes for the future.

Panelists review unmet needs in clostridium difficile infection management and consider how medical policies are evolving to address them.

Shared insight on the process to gain access to fecal microbiota transplant for patients with clostridium difficile infection.

A focused discussion on the barriers to fecal microbiota transplant for patients with clostridium difficile infection.

Experts focus on the current state of fecal microbiota transplant as a treatment option for clostridium difficile infection.

Panelists take a step back to consider the broader challenges in managing patients with clostridium difficile infection.

Payer participants consider how they proactively risk stratify patients for clostridium difficile infection recurrence.

An overview on how the cost of therapy for recurrent clostridium difficile infection may impact treatment planning.

Focused discussion on the use of fidaxomicin for clostridium difficile infection, and possible barriers to the selection of this agent.

Payer participants break down how coverage criteria are determined for treatments for clostridium difficile infection.

Shared insight on the differences between ACG and IDSA/SHEA treatment guidelines for patients with clostridium difficile infection.

A panel of experts review treatment goals and assessing response in patients with recurrent clostridium difficile infection.

A broad view on the impact of recurrent clostridium difficile infection on patients and the healthcare system at large.

Experts focus on recurrent clostridium difficile infection to define risk factors and discuss impact on patient outcomes.

Opening their discussion, panelists elucidate patient factors that may impact risk of developing clostridium difficile infection.